

Insulin glargine and its two active metabolites: A sensitive simultaneous hybrid assay coupling immunoaffinity purification support biosimilar clinical studies

Journal of Chromatography B: Analytical Technologies in the Biomedical Sciences  
1063, 50-59

DOI: [10.1016/j.jchromb.2017.08.018](https://doi.org/10.1016/j.jchromb.2017.08.018)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1092, 506-514.	1.2	19
2	Strategy for peptide quantification using LC-MS in regulated bioanalysis: case study with a glucose-responsive insulin. <i>Bioanalysis</i> , 2018, 10, 1207-1220.	0.6	5
3	Quantitation of Super Basic Peptides in Biological Matrices by a Generic Perfluoropentanoic Acid-Based Liquid Chromatography-Mass Spectrometry Method. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 1779-1789.	1.2	3
4	Comparative pharmacokinetic study on three formulations of Astragali Radix by an LC-MS/MS method for determination of formononetin in human plasma. <i>Biomedical Chromatography</i> , 2019, 33, e4563.	0.8	7
6	Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. <i>Journal of Pharmaceutical Analysis</i> , 2019, 9, 143-155.	2.4	19
8	LC-MS bioanalysis of intact proteins and peptides. <i>Biomedical Chromatography</i> , 2020, 34, e4633.	0.8	62
9	Detection of intact insulin analogues in post-mortem vitreous humour—Application to forensic toxicology casework. <i>Drug Testing and Analysis</i> , 2021, 13, 604-613.	1.6	4
10	Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 107-116.	1.1	3
11	Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 212, 114639.	1.4	1
12	Commentary: Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 843658.	1.6	0
13	A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 125-132.	2.3	0
14	Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory InputsA Part 1A Recommendations on Endogenous Compounds, Small Molecules, Tj ETQq1 1 0.784314 rgBT	0.6	14
15	Peptides and Oligonucleotide-Based Therapy: Bioanalytical Challenges and Practical Solutions. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2022, , 131-155.	0.2	1